Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX  
12.84
+0.88 (+7.36%)
Other Pre-Announcement

Biocryst Receives European Commission Approval Of Orladeyo

Published: 04/30/2021 13:43 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - Biocryst Receives European Commission Approval of Orladeyo™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients.
Biocryst Pharmaceuticals Inc - Ec Approval of Orladeyo is Applicable to All European Union Member States Plus Iceland, Norway and Liechtenstein.
Biocryst Pharmaceuticals Inc - Expects to Launch Orladeyo This Quarter in Germany, With Launches in Other European Markets to Follow.